Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2025-12-25 @ 2:34 AM
NCT ID: NCT00252434
Eligibility Criteria: Inclusion Criteria: 1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the University of California, Los Angeles (UCLA) Center for Clinical AIDS Research and Education (CARE) clinic, aged 18-65 2. Willing to give informed consent and comply with study procedures 3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications 4. Diagnosed with current methamphetamine abuse as determined by Mini-International Neuropsychiatric Interview (MINI) 5. Interested in seeking treatment for methamphetamine abuse and in participating in this research project. Exclusion Criteria: 1. Unwilling to give, or withdrawal of, informed consent 2. Inability to understand nature of study 3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision \[DSM-IV-TR\] criteria for current bipolar disorder or a psychotic disorder) 4. Current suicidal ideation or suicide attempt within the past 3 months 5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI. 6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.
Sex: MALE
Minimum Age: 18 Years
Maximum Age: 65 Years
Study: NCT00252434
Study Brief:
Protocol Section: NCT00252434